Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 39

1.

Integrin Receptors Play a Key Role in the Regulation of Hepatic CYP3A.

Jonsson-Schmunk K, Wonganan P, Choi JH, Callahan SM, Croyle MA.

Drug Metab Dispos. 2016 May;44(5):758-70. doi: 10.1124/dmd.115.068874. Epub 2016 Feb 11.

2.

A long-lasting, single-dose nasal vaccine for Ebola: a practical armament for an outbreak with significant global impact.

Jonsson-Schmunk K, Croyle MA.

Expert Rev Anti Infect Ther. 2015 May;13(5):527-30. doi: 10.1586/14787210.2015.1028368. Epub 2015 Mar 23.

3.

Bolstering Components of the Immune Response Compromised by Prior Exposure to Adenovirus: Guided Formulation Development for a Nasal Ebola Vaccine.

Choi JH, Schafer SC, Freiberg AN, Croyle MA.

Mol Pharm. 2015 Aug 3;12(8):2697-711. doi: 10.1021/mp5006454. Epub 2015 Jan 20.

4.

A Single Dose Respiratory Recombinant Adenovirus-Based Vaccine Provides Long-Term Protection for Non-Human Primates from Lethal Ebola Infection.

Choi JH, Jonsson-Schmunk K, Qiu X, Shedlock DJ, Strong J, Xu JX, Michie KL, Audet J, Fernando L, Myers MJ, Weiner D, Bajrovic I, Tran LQ, Wong G, Bello A, Kobinger GP, Schafer SC, Croyle MA.

Mol Pharm. 2015 Aug 3;12(8):2712-31. doi: 10.1021/mp500646d. Epub 2014 Nov 14.

5.

Evaluation of the HC-04 cell line as an in vitro model for mechanistic assessment of changes in hepatic cytochrome P450 3A during adenovirus infection.

Wonganan P, Jonsson-Schmunk K, Callahan SM, Choi JH, Croyle MA.

Drug Metab Dispos. 2014 Jul;42(7):1191-201. doi: 10.1124/dmd.113.056663. Epub 2014 Apr 24.

6.

Modeling pre-existing immunity to adenovirus in rodents: immunological requirements for successful development of a recombinant adenovirus serotype 5-based ebola vaccine.

Choi JH, Schafer SC, Zhang L, Juelich T, Freiberg AN, Croyle MA.

Mol Pharm. 2013 Sep 3;10(9):3342-55. doi: 10.1021/mp4001316. Epub 2013 Aug 19.

7.

Emerging targets and novel approaches to Ebola virus prophylaxis and treatment.

Choi JH, Croyle MA.

BioDrugs. 2013 Dec;27(6):565-83. doi: 10.1007/s40259-013-0046-1. Review.

8.

Induction of broad cytotoxic T cells by protective DNA vaccination against Marburg and Ebola.

Shedlock DJ, Aviles J, Talbott KT, Wong G, Wu SJ, Villarreal DO, Myles DJ, Croyle MA, Yan J, Kobinger GP, Weiner DB.

Mol Ther. 2013 Jul;21(7):1432-44. doi: 10.1038/mt.2013.61. Epub 2013 May 14.

9.

A single sublingual dose of an adenovirus-based vaccine protects against lethal Ebola challenge in mice and guinea pigs.

Choi JH, Schafer SC, Zhang L, Kobinger GP, Juelich T, Freiberg AN, Croyle MA.

Mol Pharm. 2012 Jan 1;9(1):156-67. doi: 10.1021/mp200392g. Epub 2011 Dec 15.

10.

Optimized adenovirus-antibody complexes stimulate strong cellular and humoral immune responses against an encoded antigen in naive mice and those with preexisting immunity.

Choi JH, Dekker J, Schafer SC, John J, Whitfill CE, Petty CS, Haddad EE, Croyle MA.

Clin Vaccine Immunol. 2012 Jan;19(1):84-95. doi: 10.1128/CVI.05319-11. Epub 2011 Nov 16.

11.

Species differences in the pharmacology and toxicology of PEGylated helper-dependent adenovirus.

Wonganan P, Clemens CC, Brasky K, Pastore L, Croyle MA.

Mol Pharm. 2011 Feb 7;8(1):78-92. doi: 10.1021/mp100216h. Epub 2010 Sep 23.

12.

Recent advances in Ebolavirus vaccine development.

Richardson JS, Dekker JD, Croyle MA, Kobinger GP.

Hum Vaccin. 2010 Jun;6(6):439-49. Epub 2010 Jun 1. Review.

PMID:
20671437
13.

PEGylated Adenoviruses: From Mice to Monkeys.

Wonganan P, Croyle MA.

Viruses. 2010 Feb;2(2):468-502. doi: 10.3390/v2020468. Epub 2010 Feb 1.

14.

Development of a nasal adenovirus-based vaccine: Effect of concentration and formulation on adenovirus stability and infectious titer during actuation from two delivery devices.

Renteria SS, Clemens CC, Croyle MA.

Vaccine. 2010 Feb 25;28(9):2137-48. doi: 10.1016/j.vaccine.2009.12.025. Epub 2009 Dec 29.

PMID:
20044048
15.

Long-term virus-induced alterations of CYP3A-mediated drug metabolism: a look at the virology, immunology and molecular biology of a multi-faceted problem.

Croyle MA.

Expert Opin Drug Metab Toxicol. 2009 Oct;5(10):1189-211. doi: 10.1517/17425250903136748. Review.

PMID:
19732028
16.

Enhanced protection against Ebola virus mediated by an improved adenovirus-based vaccine.

Richardson JS, Yao MK, Tran KN, Croyle MA, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2009;4(4):e5308. doi: 10.1371/journal.pone.0005308. Epub 2009 Apr 23.

17.

Drug-virus interaction: effect of administration of recombinant adenoviruses on the pharmacokinetics of docetaxel in a rat model.

Wonganan P, Zamboni WC, Strychor S, Dekker JD, Croyle MA.

Cancer Gene Ther. 2009 May;16(5):405-14. doi: 10.1038/cgt.2008.99. Epub 2008 Dec 26.

18.

Nasal delivery of an adenovirus-based vaccine bypasses pre-existing immunity to the vaccine carrier and improves the immune response in mice.

Croyle MA, Patel A, Tran KN, Gray M, Zhang Y, Strong JE, Feldmann H, Kobinger GP.

PLoS One. 2008;3(10):e3548. doi: 10.1371/journal.pone.0003548. Epub 2008 Oct 29.

19.
20.

Influence of method of systemic administration of adenovirus on virus-mediated toxicity: focus on mortality, virus distribution, and drug metabolism.

Boquet MP, Wonganan P, Dekker JD, Croyle MA.

J Pharmacol Toxicol Methods. 2008 Nov-Dec;58(3):222-32. doi: 10.1016/j.vascn.2008.07.003. Epub 2008 Aug 3.

21.

Controlled inactivation of recombinant viruses with vitamin B2.

Callahan SM, Wonganan P, Obenauer-Kutner LJ, Sutjipto S, Dekker JD, Croyle MA.

J Virol Methods. 2008 Mar;148(1-2):132-45. Epub 2007 Dec 21.

22.

Renal pathophysiology after systemic administration of recombinant adenovirus: changes in renal cytochromes P450 based on vector dose.

Le HT, Boquet MP, Clark EA, Callahan SM, Croyle MA.

Hum Gene Ther. 2006 Nov;17(11):1095-111.

PMID:
17069534
23.

Impact of transgene expression on drug metabolism following systemic adenoviral vector administration.

Callahan SM, Boquet MP, Ming X, Brunner LJ, Croyle MA.

J Gene Med. 2006 May;8(5):566-76.

PMID:
16508909
24.

Utility of PEGylated recombinant adeno-associated viruses for gene transfer.

Le HT, Yu QC, Wilson JM, Croyle MA.

J Control Release. 2005 Nov 2;108(1):161-77. Epub 2005 Aug 26.

PMID:
16125817
25.

PEGylated helper-dependent adenoviral vectors: highly efficient vectors with an enhanced safety profile.

Croyle MA, Le HT, Linse KD, Cerullo V, Toietta G, Beaudet A, Pastore L.

Gene Ther. 2005 Apr;12(7):579-87.

PMID:
15647765
26.

Considerations for use of recombinant adenoviral vectors: dose effect on hepatic cytochromes P450.

Callahan SM, Ming X, Lu SK, Brunner LJ, Croyle MA.

J Pharmacol Exp Ther. 2005 Feb;312(2):492-501. Epub 2004 Oct 20.

PMID:
15496614
27.

PEGylation of a vesicular stomatitis virus G pseudotyped lentivirus vector prevents inactivation in serum.

Croyle MA, Callahan SM, Auricchio A, Schumer G, Linse KD, Wilson JM, Brunner LJ, Kobinger GP.

J Virol. 2004 Jan;78(2):912-21.

28.

PEGylated adenoviruses for gene delivery to the intestinal epithelium by the oral route.

Cheng X, Ming X, Croyle MA.

Pharm Res. 2003 Sep;20(9):1444-51.

PMID:
14567640
29.

PEGylation of E1-deleted adenovirus vectors allows significant gene expression on readministration to liver.

Croyle MA, Chirmule N, Zhang Y, Wilson JM.

Hum Gene Ther. 2002 Oct 10;13(15):1887-900.

PMID:
12396620
30.
31.
33.
34.

In vitro and in vivo assessment of adenovirus 41 as a vector for gene delivery to the intestine.

Croyle MA, Stone M, Amidon GL, Roessler BJ.

Gene Ther. 1998 May;5(5):645-54.

35.

Beta cyclodextrins enhance adenoviral-mediated gene delivery to the intestine.

Croyle MA, Roessler BJ, Hsu CP, Sun R, Amidon GL.

Pharm Res. 1998 Sep;15(9):1348-55.

36.

Factors that influence stability of recombinant adenoviral preparations for human gene therapy.

Croyle MA, Roessler BJ, Davidson BL, Hilfinger JM, Amidon GL.

Pharm Dev Technol. 1998 Aug;3(3):373-83.

PMID:
9742558
37.

Development of a highly efficient purification process for recombinant adenoviral vectors for oral gene delivery.

Croyle MA, Anderson DJ, Roessler BJ, Amidon GL.

Pharm Dev Technol. 1998 Aug;3(3):365-72.

PMID:
9742557
38.

Role of integrin expression in adenovirus-mediated gene delivery to the intestinal epithelium.

Croyle MA, Walter E, Janich S, Roessler BJ, Amidon GL.

Hum Gene Ther. 1998 Mar 1;9(4):561-73.

Supplemental Content

Loading ...
Support Center